Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of Ischemia Modified Albumin (IMA) in Sepsis

NCT00448968 is registered in ClinicalTrials.gov with Inverness Medical Innovations as lead sponsor.

NCT NCT00448968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
Lead sponsor
Inverness Medical Innovations
Phase
Observational
Overall status
Completed
Start date
March 31, 2007
Completion date
September 30, 2007
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis, sepsis syndrome, severe sepsis, systemic inflammatory response syndrome